CN1152032C - 吡啶基链烷烃-和吡啶基链炔径-酸酰胺作为细胞抑制剂和免疫抑制剂 - Google Patents
吡啶基链烷烃-和吡啶基链炔径-酸酰胺作为细胞抑制剂和免疫抑制剂 Download PDFInfo
- Publication number
- CN1152032C CN1152032C CNB971974241A CN97197424A CN1152032C CN 1152032 C CN1152032 C CN 1152032C CN B971974241 A CNB971974241 A CN B971974241A CN 97197424 A CN97197424 A CN 97197424A CN 1152032 C CN1152032 C CN 1152032C
- Authority
- CN
- China
- Prior art keywords
- hydrogen
- group
- alkyl
- substituted
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/59—Hydrogenated pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Catalysts (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19624659A DE19624659A1 (de) | 1996-06-20 | 1996-06-20 | Neue Pyridylalken- und Pyridylalkinsäureamide |
| DE19624659.8 | 1996-06-20 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2004100325866A Division CN1546472A (zh) | 1996-06-20 | 1997-06-20 | 吡啶基链烷烃-和吡啶基链炔径-酸酰胺作为细胞抑制剂和免疫抑制剂 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1228777A CN1228777A (zh) | 1999-09-15 |
| CN1152032C true CN1152032C (zh) | 2004-06-02 |
Family
ID=7797501
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB971974241A Expired - Fee Related CN1152032C (zh) | 1996-06-20 | 1997-06-20 | 吡啶基链烷烃-和吡啶基链炔径-酸酰胺作为细胞抑制剂和免疫抑制剂 |
| CNA2004100325866A Pending CN1546472A (zh) | 1996-06-20 | 1997-06-20 | 吡啶基链烷烃-和吡啶基链炔径-酸酰胺作为细胞抑制剂和免疫抑制剂 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2004100325866A Pending CN1546472A (zh) | 1996-06-20 | 1997-06-20 | 吡啶基链烷烃-和吡啶基链炔径-酸酰胺作为细胞抑制剂和免疫抑制剂 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US7241745B2 (enExample) |
| EP (1) | EP0923570B1 (enExample) |
| JP (1) | JP4225572B2 (enExample) |
| CN (2) | CN1152032C (enExample) |
| AT (1) | ATE224888T1 (enExample) |
| AU (1) | AU736206B2 (enExample) |
| BR (1) | BR9709823B1 (enExample) |
| CA (1) | CA2257448C (enExample) |
| CZ (1) | CZ291791B6 (enExample) |
| DE (2) | DE19624659A1 (enExample) |
| DK (1) | DK0923570T3 (enExample) |
| ES (1) | ES2179351T3 (enExample) |
| HU (1) | HU225715B1 (enExample) |
| IL (1) | IL127352A (enExample) |
| PT (1) | PT923570E (enExample) |
| RU (1) | RU2200734C2 (enExample) |
| TR (1) | TR199802651T2 (enExample) |
| WO (1) | WO1997048696A1 (enExample) |
| ZA (1) | ZA975437B (enExample) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105492437A (zh) * | 2013-07-03 | 2016-04-13 | 卡尔约药物治疗公司 | 取代的苯并呋喃基和苯并噁唑基化合物及其用途 |
| US9994558B2 (en) | 2013-09-20 | 2018-06-12 | Karyopharm Therapeutics Inc. | Multicyclic compounds and methods of using same |
| US10363247B2 (en) | 2015-08-18 | 2019-07-30 | Karyopharm Therapeutics Inc. | (S,E)-3-(6-aminopyridin-3-yl)-N-((5-(4-(3-fluoro-3-methylpyrrolidine-1-carbonyl)phenyl-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer |
| US10858347B2 (en) | 2015-12-31 | 2020-12-08 | Karyopharm Therapeutics Inc. | Multicyclic compounds and uses thereof |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19624659A1 (de) * | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalken- und Pyridylalkinsäureamide |
| DE19756261A1 (de) * | 1997-12-17 | 1999-07-01 | Klinge Co Chem Pharm Fab | Neue arylsubstituierte Pyridylalkan-, alken- und alkincarbonsäureamide |
| DE19756236A1 (de) * | 1997-12-17 | 1999-07-01 | Klinge Co Chem Pharm Fab | Neue piperazinylsubstituierte Pyridylalkan-, alken- und -alkincarbonsäureamide |
| DE19756235A1 (de) * | 1997-12-17 | 1999-07-01 | Klinge Co Chem Pharm Fab | Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide |
| DE19756212A1 (de) * | 1997-12-17 | 1999-07-01 | Klinge Co Chem Pharm Fab | Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide |
| DE19818044A1 (de) * | 1998-04-22 | 1999-10-28 | Klinge Co Chem Pharm Fab | Verwendung von Vitamin-PP-Verbindungen |
| PT1131291E (pt) * | 1998-11-17 | 2005-01-31 | Hoffmann La Roche | Antagonistas iii do receptor 4-aroil-piperidin-ccr-3 |
| EP1031564A1 (en) | 1999-02-26 | 2000-08-30 | Klinge Pharma GmbH | Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy |
| US6432432B1 (en) | 1999-03-05 | 2002-08-13 | Arch Chemicals, Inc. | Chemical method of making a suspension, emulsion or dispersion of pyrithione particles |
| CO5180550A1 (es) | 1999-04-19 | 2002-07-30 | Smithkline Beecham Corp | Inhibidores de fab i |
| AR024158A1 (es) | 1999-06-01 | 2002-09-04 | Smithkline Beecham Corp | Compuestos antibacterianos |
| US6730684B1 (en) | 1999-10-08 | 2004-05-04 | Affinium Pharmaceuticals, Inc. | Fab I inhibitors |
| DE60017180T2 (de) | 1999-10-08 | 2005-12-08 | Affinium Pharmaceuticals, Inc., Toronto | Fab i inhibitoren |
| US6762201B1 (en) | 1999-10-08 | 2004-07-13 | Affinium Pharmaceuticals, Inc. | Fab I inhibitors |
| CA2444597A1 (en) | 2001-04-06 | 2002-10-06 | Affinium Pharmaceuticals, Inc. | Fab i inhibitors |
| FR2823975B1 (fr) * | 2001-04-27 | 2003-05-30 | Sanofi Synthelabo | Nouvelle utilisation de pyridoindolone |
| EP1348434A1 (en) * | 2002-03-27 | 2003-10-01 | Fujisawa Deutschland GmbH | Use of pyridyl amides as inhibitors of angiogenesis |
| BRPI0406761A (pt) | 2003-01-14 | 2005-12-20 | Arena Pharm Inc | Derivados de arila e heteroarila 1,2,3-trissubstituìdos como moduladores do metabolismo e a profilaxia e tratamento de distúrbios relacionados a estes tais como diabetes e hiper-glicemia |
| EP1768662A2 (en) | 2004-06-24 | 2007-04-04 | Novartis Vaccines and Diagnostics, Inc. | Small molecule immunopotentiators and assays for their detection |
| DOP2006000010A (es) | 2005-01-10 | 2006-07-31 | Arena Pharm Inc | Procedimiento para preparar eteres aromáticos |
| US20110045065A1 (en) * | 2005-07-11 | 2011-02-24 | Ashok Vasantray Vyas | Substance having antioxidant, geroprotective and anti-ischemic activity and method for the preparation thereof |
| WO2007053498A1 (en) | 2005-11-01 | 2007-05-10 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of ccr2 |
| US8067415B2 (en) | 2005-11-01 | 2011-11-29 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of CCR2 |
| WO2008009122A1 (en) | 2006-07-20 | 2008-01-24 | Affinium Pharmaceuticals, Inc. | Acrylamide derivatives as fab i inhibitors |
| WO2008026018A1 (en) | 2006-09-01 | 2008-03-06 | Topotarget Switzerland Sa | New method for the treatment of inflammatory diseases |
| EP2125802A4 (en) | 2007-02-16 | 2014-08-20 | Debiopharm Int Sa | SALTS, PRODRUGS AND POLYMORPHES OF FAB I INHIBITORS |
| EP2098231A1 (en) | 2008-03-05 | 2009-09-09 | Topotarget Switzerland SA | Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury |
| US9006426B2 (en) | 2008-06-24 | 2015-04-14 | Topotarget A/S | Squaric acid derivatives as inhibitors of the nicotinamide |
| RU2011111728A (ru) | 2008-08-29 | 2012-10-10 | Топотаргет А/С (Dk) | Новые производные мочевины и тиомочевины |
| WO2010130178A1 (zh) * | 2009-05-12 | 2010-11-18 | Sun Shuping | 丙烯酰胺类衍生物及其制备药物的用途 |
| CA2768338A1 (en) | 2009-07-17 | 2011-01-20 | Topotarget A/S | Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors |
| WO2011121055A1 (en) | 2010-03-31 | 2011-10-06 | Topotarget A/S | Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety |
| TW201217359A (en) | 2010-09-03 | 2012-05-01 | Forma Therapeutics Inc | Novel compounds and compositions for the inhibition of NAMPT |
| SG188367A1 (en) | 2010-09-03 | 2013-04-30 | Forma Tm Llc | Novel compounds and compositions for the inhibition of nampt |
| JP5881705B2 (ja) | 2010-09-03 | 2016-03-09 | フォーマ ティーエム， エルエルシー． | Ｎａｍｐｔの阻害のための新規化合物及び組成物 |
| SG188548A1 (en) | 2010-09-22 | 2013-04-30 | Arena Pharm Inc | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| BR112013006030B1 (pt) * | 2010-09-29 | 2020-03-17 | Intervet International B.V. | Composto e sais ou n-óxidos farmaceuticamente aceitáveis, e, uso do composto |
| UY33726A (es) | 2010-11-15 | 2012-06-29 | Abbott Lab | Inhibidores de nampt y rock |
| EP2640704A1 (en) | 2010-11-15 | 2013-09-25 | Abbvie Inc. | Nampt inhibitors |
| KR20140027366A (ko) | 2011-05-04 | 2014-03-06 | 포르마 티엠, 엘엘씨. | Nampt의 억제를 위한 신규 화합물 및 조성물 |
| AR082889A1 (es) | 2011-05-09 | 2013-01-16 | Forma Therapeutics Inc | Compuestos y composiciones para la inhibicion de nampt |
| ES2655645T3 (es) | 2011-07-29 | 2018-02-21 | Karyopharm Therapeutics, Inc. | Moduladores de transporte nuclear que contienen hidrazida y usos de los mismos |
| PL3404027T3 (pl) * | 2012-05-09 | 2020-09-21 | Biogen Ma Inc. | Modulatory transportu jądrowego i ich zastosowania |
| WO2013170118A1 (en) | 2012-05-11 | 2013-11-14 | Abbvie Inc. | Thiazolecarboxamide derivatives for use as nampt inhibitors |
| CA2873075A1 (en) | 2012-05-11 | 2013-07-14 | Abbvie Inc. | Nampt inhibitors |
| CA2873097A1 (en) | 2012-05-11 | 2013-11-14 | Todd M. Hansen | Pyridazine and pyridine derivatives as nampt inhibitors |
| HK1208221A1 (en) | 2012-05-11 | 2016-02-26 | Abbvie Inc. | Nampt inhibitors |
| DK2861608T3 (da) | 2012-06-19 | 2019-06-24 | Debiopharm Int Sa | Prodrug-derivater af (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamid |
| EP2925750A1 (en) * | 2012-11-29 | 2015-10-07 | Karyopharm Therapeutics, Inc. | Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof |
| WO2014144772A1 (en) | 2013-03-15 | 2014-09-18 | Karyopharm Therapeutics Inc. | Methods of promoting wound healing using crm1 inhibitors |
| LT3010892T (lt) | 2013-06-21 | 2019-04-10 | Karyopharm Therapeutics Inc. | 1,2,4-triazolai kaip branduolio transporto moduliatoriai ir jų panaudojimas |
| JP2016532648A (ja) * | 2013-10-09 | 2016-10-20 | イーライ リリー アンド カンパニー | Ｎａｍｐｔ阻害剤として有用な新規ピリジルオキシアセチルテトラヒドロイソキノリン化合物 |
| EP3172205A1 (en) | 2014-07-23 | 2017-05-31 | Aurigene Discovery Technologies Limited | 4,5-dihydroisoxazole derivatives as nampt inhibitors |
| DK3180331T3 (da) | 2014-08-15 | 2022-09-12 | Karyopharm Therapeutics Inc | Polymorfer af selinexor |
| AU2016205361C1 (en) | 2015-01-06 | 2021-04-08 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| CN104447483B (zh) * | 2015-01-13 | 2016-07-27 | 佛山市赛维斯医药科技有限公司 | 含苯胺和二烯金刚烷结构的化合物、其制备方法和用途 |
| CN104447484B (zh) * | 2015-01-13 | 2016-06-08 | 佛山市赛维斯医药科技有限公司 | 含烷氧苯基和二烯金刚烷结构的化合物、其制备方法和用途 |
| CN104447486B (zh) * | 2015-01-13 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | 二烯氟代金刚烷类化合物、其制备方法和用途 |
| CA3002551A1 (en) | 2015-06-22 | 2016-12-29 | Arena Pharmaceuticals, Inc. | Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(com pound 1)for use in s1p1 receptor-associated disorders |
| TWI730985B (zh) * | 2015-09-15 | 2021-06-21 | 美商艾森伯利生物科學公司 | B型肝炎核心蛋白質調節劑 |
| EP3397633A1 (en) | 2015-12-31 | 2018-11-07 | Karyopharm Therapeutics, Inc. | Nuclear transport modulators and uses thereof |
| MA43530A (fr) | 2015-12-31 | 2018-11-07 | Karyopharm Therapeutics Inc | Modulateurs de transport nucléaire et leurs utilisations |
| BR112018016721A2 (pt) | 2016-02-26 | 2018-12-26 | Debiopharm Int Sa | uso de di-hidrogeno fosfato de {6-[(e)-3-{metil[(3-metil-1-benfofuran-2-iol)metil]amino)-3-xopro-1-en-1-il]-2-oxo-3,4-di-hidro-1,8-naftiridin-1(2h)-il}metila e composição farmacêutica para tratamento de infecções bacterianas associadas ao pé diabético |
| EP3279192A1 (en) * | 2016-08-05 | 2018-02-07 | Centre Hospitalier Universitaire Vaudois (CHUV) | Piperidine derivatives for use in the treatment of pancreatic cancer |
| WO2018086703A1 (en) | 2016-11-11 | 2018-05-17 | Bayer Pharma Aktiengesellschaft | Dihydropyridazinones substituted with phenylureas |
| WO2018098472A1 (en) | 2016-11-28 | 2018-05-31 | Karyopharm Therapeutics Inc. | Crm1 inhibitors for treating epilepsy |
| CN107827897A (zh) * | 2017-10-23 | 2018-03-23 | 青岛大学 | 一种手性七元螺环吲哚酮类化合物的合成方法 |
| CA3089754A1 (en) | 2018-01-31 | 2019-08-08 | Bayer Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
| CN108558840B (zh) * | 2018-06-04 | 2020-11-06 | 上海交通大学 | 水溶性氮杂α-萘黄酮类化合物及其制备方法和医药用途 |
| CA3102136A1 (en) | 2018-06-06 | 2019-12-12 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
| LT3923914T (lt) | 2019-02-14 | 2023-07-25 | Debiopharm International S.A. | Afabicino kompozicija, jos gamybos būdas |
| CA3139942A1 (en) | 2019-06-14 | 2020-12-17 | Justyna NOWAKOWSKA | Medicament and use thereof for treating bacterial infections involving biofilm |
| WO2021013693A1 (en) | 2019-07-23 | 2021-01-28 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
| US20230023124A1 (en) | 2019-11-06 | 2023-01-26 | Remedy Plan, Inc. | Cancer treatments targeting cancer stem cells |
| EP4337639A1 (en) | 2021-05-13 | 2024-03-20 | Remedy Plan, Inc. | Nampt inhibitors and uses thereof |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4283541A (en) | 1980-05-27 | 1981-08-11 | Usv Pharmaceutical Corporation | Pyridylacyl-hydroxamates |
| NL8005133A (nl) | 1980-09-12 | 1982-04-01 | Duphar Int Res | Fenylpiperazinederivaten met antiagressieve werking. |
| US5326772A (en) | 1984-09-28 | 1994-07-05 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Diaryl compounds for their use |
| US4778796A (en) | 1985-07-19 | 1988-10-18 | Dainippon Pharmaceutical Co., Ltd. | ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same |
| DE3641822A1 (de) | 1986-12-06 | 1988-06-16 | Goedecke Ag | Verwendung von dihydrophenylaminosaeurederivaten und diese enthaltende arzneimittel zur immunmodulation und cytostase |
| JPS63179869A (ja) | 1987-01-20 | 1988-07-23 | Dainippon Pharmaceut Co Ltd | ピペリジン誘導体 |
| JP2832979B2 (ja) * | 1988-02-15 | 1998-12-09 | 武田薬品工業株式会社 | 不飽和カルボン酸アミド誘導体 |
| HU206181B (en) | 1988-02-19 | 1992-09-28 | Byk Gulden Lomberg Chem Fab | Process for producing pharmaceutical compositions comprising optically pure r-(+)-niguldipin and its derivatives and suitable for treating tumoros diseases |
| EP0343307A1 (en) * | 1988-05-26 | 1989-11-29 | Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. | 4-Piperidinealkanamine derivatives |
| IE903196A1 (en) | 1989-09-05 | 1991-03-13 | Searle & Co | Substituted n-benzylpiperidine amides |
| US5125957A (en) * | 1989-11-01 | 1992-06-30 | Sumitomo Chemical Company, Limited | Pyrimidine derivatives |
| IE903957A1 (en) | 1989-11-06 | 1991-05-08 | Sanofi Sa | Aromatic amine compounds, their method of preparation and¹pharmaceutical compositions in which they are present |
| EP0525023A1 (de) | 1990-04-10 | 1993-02-03 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Neue pyridinester |
| AU652747B2 (en) | 1990-04-10 | 1994-09-08 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Pyridines as medicaments |
| DE4020570A1 (de) | 1990-06-28 | 1992-01-02 | Hoechst Ag | 2,4- und 2,5-substituierte pyridin-n-oxide, verfahren zu deren herstellung sowie deren verwendung |
| US5260323A (en) | 1990-06-28 | 1993-11-09 | Hoechst Aktiengesellschaft | 2,4- and 2,5-substituted pyridine-N-oxides, processes for their preparation and their use |
| CA2048110C (en) | 1990-07-30 | 2002-06-25 | Muneo Takatani | Imidazopyridine derivatives and their use |
| US5229400A (en) | 1990-10-05 | 1993-07-20 | Ajinomoto Co., Inc. | Piperidine compounds and their use as antiarrhythmic agents |
| FR2676053B1 (fr) | 1991-05-03 | 1993-08-27 | Sanofi Elf | Nouveaux composes dialkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| EP0612729B1 (en) | 1991-05-10 | 1997-04-23 | Takeda Chemical Industries, Ltd. | Pyridine derivatives, their production and use |
| US5208247A (en) | 1991-08-01 | 1993-05-04 | American Cyanamid Company | Pyridinium compounds which are useful as antagonists of platelet activating factor |
| EP0548883A1 (de) | 1991-12-24 | 1993-06-30 | Hoechst Aktiengesellschaft | Substituierte Pyridin-N-oxide, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel |
| WO1993013083A1 (en) | 1991-12-31 | 1993-07-08 | Fujisawa Pharmaceutical Co., Ltd. | Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity |
| FR2686084B1 (fr) | 1992-01-10 | 1995-12-22 | Bioprojet Soc Civ | Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques. |
| GB9200535D0 (en) | 1992-01-10 | 1992-02-26 | Fujisawa Pharmaceutical Co | New compound |
| WO1994001402A1 (en) | 1992-07-13 | 1994-01-20 | Merck Sharp & Dohme Limited | Heterocyclic amide derivatives as tachykinin derivatives |
| AU699043B2 (en) | 1993-10-15 | 1998-11-19 | Schering Corporation | Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
| IL111235A (en) | 1993-10-15 | 2001-03-19 | Schering Plough Corp | Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them |
| IL111257A0 (en) | 1993-10-15 | 1994-12-29 | Schering Corp | Tricyclic sulfonamide compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
| AU698313B2 (en) | 1994-03-14 | 1998-10-29 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents |
| US5712280A (en) | 1995-04-07 | 1998-01-27 | Schering Corporation | Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
| IL117798A (en) | 1995-04-07 | 2001-11-25 | Schering Plough Corp | Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them |
| FR2738245B1 (fr) | 1995-08-28 | 1997-11-21 | Sanofi Sa | Nouveaux derives de piperidine, procede pour leur obtention et compositions pharmaceutiques les contenant |
| US6451816B1 (en) * | 1997-06-20 | 2002-09-17 | Klinge Pharma Gmbh | Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression |
| DE19624659A1 (de) * | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalken- und Pyridylalkinsäureamide |
| DE19624668A1 (de) | 1996-06-20 | 1998-02-19 | Klinge Co Chem Pharm Fab | Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden |
| DE19624704A1 (de) * | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalkansäureamide |
-
1996
- 1996-06-20 DE DE19624659A patent/DE19624659A1/de not_active Ceased
-
1997
- 1997-06-19 ZA ZA9705437A patent/ZA975437B/xx unknown
- 1997-06-20 ES ES97928261T patent/ES2179351T3/es not_active Expired - Lifetime
- 1997-06-20 EP EP97928261A patent/EP0923570B1/en not_active Expired - Lifetime
- 1997-06-20 DE DE69715888T patent/DE69715888T2/de not_active Expired - Lifetime
- 1997-06-20 CZ CZ19984093A patent/CZ291791B6/cs not_active IP Right Cessation
- 1997-06-20 CN CNB971974241A patent/CN1152032C/zh not_active Expired - Fee Related
- 1997-06-20 HU HU9903766A patent/HU225715B1/hu not_active IP Right Cessation
- 1997-06-20 DK DK97928261T patent/DK0923570T3/da active
- 1997-06-20 AT AT97928261T patent/ATE224888T1/de active
- 1997-06-20 BR BRPI9709823-0B1A patent/BR9709823B1/pt not_active IP Right Cessation
- 1997-06-20 RU RU99101069/04A patent/RU2200734C2/ru not_active IP Right Cessation
- 1997-06-20 CN CNA2004100325866A patent/CN1546472A/zh active Pending
- 1997-06-20 JP JP50231898A patent/JP4225572B2/ja not_active Expired - Fee Related
- 1997-06-20 CA CA002257448A patent/CA2257448C/en not_active Expired - Fee Related
- 1997-06-20 IL IL12735297A patent/IL127352A/xx not_active IP Right Cessation
- 1997-06-20 PT PT97928261T patent/PT923570E/pt unknown
- 1997-06-20 TR TR1998/02651T patent/TR199802651T2/xx unknown
- 1997-06-20 AU AU32625/97A patent/AU736206B2/en not_active Ceased
- 1997-06-20 WO PCT/EP1997/003245 patent/WO1997048696A1/en not_active Ceased
-
2002
- 2002-08-05 US US10/213,952 patent/US7241745B2/en not_active Expired - Fee Related
-
2006
- 2006-12-07 US US11/635,157 patent/US20070219197A1/en not_active Abandoned
-
2007
- 2007-02-26 US US11/678,980 patent/US20070142377A1/en not_active Abandoned
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105492437A (zh) * | 2013-07-03 | 2016-04-13 | 卡尔约药物治疗公司 | 取代的苯并呋喃基和苯并噁唑基化合物及其用途 |
| CN105492437B (zh) * | 2013-07-03 | 2018-05-11 | 卡尔约药物治疗公司 | 取代的苯并呋喃基和苯并噁唑基化合物及其用途 |
| CN108440515A (zh) * | 2013-07-03 | 2018-08-24 | 卡尔约药物治疗公司 | 取代的苯并呋喃基和苯并噁唑基化合物及其用途 |
| US12331040B2 (en) | 2013-07-03 | 2025-06-17 | Karyopharm Therapeutics Inc. | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof |
| US9994558B2 (en) | 2013-09-20 | 2018-06-12 | Karyopharm Therapeutics Inc. | Multicyclic compounds and methods of using same |
| US10363247B2 (en) | 2015-08-18 | 2019-07-30 | Karyopharm Therapeutics Inc. | (S,E)-3-(6-aminopyridin-3-yl)-N-((5-(4-(3-fluoro-3-methylpyrrolidine-1-carbonyl)phenyl-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer |
| US10858347B2 (en) | 2015-12-31 | 2020-12-08 | Karyopharm Therapeutics Inc. | Multicyclic compounds and uses thereof |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1152032C (zh) | 吡啶基链烷烃-和吡啶基链炔径-酸酰胺作为细胞抑制剂和免疫抑制剂 | |
| CN1221262C (zh) | 治疗炎性疾病的酞嗪衍生物 | |
| CN1044117C (zh) | 用于抑制人免疫缺陷病毒蛋白酶的化合物及其制备方法和药物用途 | |
| JP4570247B2 (ja) | 新規なピペリジニル−置換ピリジルアルカン、アルケン及びアルキンカルボキサミド類 | |
| CN1684964A (zh) | 一些新的咪唑并吡啶及其用途 | |
| CN1688527A (zh) | 稠合的苯衍生物以及用途 | |
| CN102498091B (zh) | 甘氨酸化合物 | |
| WO2019149922A1 (en) | Compounds which cause degradation of egfr, for use against cancer | |
| CN1568187A (zh) | 2h－2,3－二氮杂萘－1－酮和其使用方法 | |
| CN1315950A (zh) | 作为5－ht4受体拮抗剂的二氢苯并二噁烯羧酰胺与酮衍生物 | |
| CN110240629B (zh) | 蛋白降解靶向bcr-abl化合物及其抗肿瘤应用 | |
| CN1141043A (zh) | 非肽类速激肽受体拮抗剂 | |
| AU2016202535A1 (en) | Fused heterocyclic compounds as sodium channel modulators | |
| CN1444582A (zh) | 杂环化合物,它们的制备和用途 | |
| CN101501028A (zh) | 2-（杂环基苄基）哒嗪酮衍生物 | |
| TW200819439A (en) | 2-amino-5-substituted pyrimidine inhibitors | |
| CN1929737A (zh) | Hiv整合酶抑制剂 | |
| CN1511151A (zh) | 3-喹啉-2(1h)-亚基二氢吲哚-2-酮衍生物 | |
| CN1414960A (zh) | 经取代的哌啶,含有这些化合物的药物组合物,及其制备方法 | |
| CN1615305A (zh) | 香豆素衍生物、生产它们的方法及其用途 | |
| CN1816541A (zh) | Vr－1拮抗剂取代－1－酞嗪胺 | |
| CN1303384A (zh) | 吡咯并[1,2－a]吡嗪sPLA2抑制剂 | |
| CN101061112A (zh) | 作为c－Kit原癌基因抑制剂的（螺环基酰氨基）氨基噻吩化合物 | |
| CN1310911C (zh) | 作为脑缺血性疾病和cns疾病治疗剂的哌嗪苯并噻唑 | |
| CN1214632A (zh) | 艾滋病治疗剂或预防剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: ASTELLAS GERMANY CO., LTD. Free format text: FORMER OWNER: ASTELLAS PHARMACEUTICAL CO., LTD. Effective date: 20080516 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C56 | Change in the name or address of the patentee |
Owner name: FUJISAWA GERMANY CO., LTD. Free format text: FORMER NAME OR ADDRESS: KLINGER PHARMACY CO.,LTD. Owner name: ASTELLAS PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME OR ADDRESS: FUJISAWA GERMANY CO., LTD. |
|
| CP03 | Change of name, title or address |
Address after: Munich, Federal Republic of Germany Patentee after: The government of Tailai pharmaceutical LLC Address before: Munich, Federal Republic of Germany Patentee before: Fujisawa German LLC Address after: Munich, Federal Republic of Germany Patentee after: Fujisawa German LLC Address before: Munich, Federal Republic of Germany Patentee before: Klinge Pharma GMBH |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20080516 Address after: Munich, Federal Republic of Germany Patentee after: Tailai aines German LLC Address before: Munich, Federal Republic of Germany Patentee before: The government of Tailai pharmaceutical LLC |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20040602 Termination date: 20120620 |